Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl E Ruby

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2009
OX40-enhanced tumor rejection and effector T cell differentiation decreases with ageCarl E Ruby, Andrew D Weinberg
Cancer Immunology, Immunotherapy : CII|March 17, 2009
The effect of aging on OX40 agonist-mediated cancer immunotherapyCarl E Ruby, Andrew D Weinberg
Molecular Pharmacology|August 16, 2002
2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affectedCarl E Ruby, Mark Leid, Nancy I Kerkvliet
Critical Reviews in Immunology|June 23, 2009
The role of OX40-mediated co-stimulation in T-cell activation and survivalWilliam L Redmond, Carl E Ruby, Andrew D Weinberg
Journal of Immunotoxicology|October 30, 2008
2,3,7,8 Tetrachlorodibenzo-p-Dioxin (TCDD) Directly Enhances the Maturation and Apoptosis of Dendritic Cells In VitroCarl E Ruby, Castle J Funatake, Nancy I Kerkvliet
European Journal of Immunology|December 22, 2006
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responsesCarl E Ruby, William L Redmond, Daniel Haley, et al.
Journal for Immunotherapy of Cancer|June 28, 2014
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanomaHoward L Kaufman, Carl E Ruby, Tasha Hughes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
IL-12 is required for anti-OX40-mediated CD4 T cell survivalCarl E Ruby, Ryan Montler, Rongxui Zheng, et al.
European Journal of Immunology|March 15, 2011
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survivalNicole A Vasilevsky, Carl E Ruby, Peter J Hurlin, et al.
Journal of Leukocyte Biology|April 10, 2014
Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell primingMichelle Farazi, Zachary Cohn, Justine Nguyen, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2009
OX40-enhanced tumor rejection and effector T cell differentiation decreases with ageCarl E Ruby, Andrew D Weinberg
Cancer Immunology, Immunotherapy : CII|March 17, 2009
The effect of aging on OX40 agonist-mediated cancer immunotherapyCarl E Ruby, Andrew D Weinberg
Molecular Pharmacology|August 16, 2002
2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affectedCarl E Ruby, Mark Leid, Nancy I Kerkvliet
Critical Reviews in Immunology|June 23, 2009
The role of OX40-mediated co-stimulation in T-cell activation and survivalWilliam L Redmond, Carl E Ruby, Andrew D Weinberg
Journal of Immunotoxicology|October 30, 2008
2,3,7,8 Tetrachlorodibenzo-p-Dioxin (TCDD) Directly Enhances the Maturation and Apoptosis of Dendritic Cells In VitroCarl E Ruby, Castle J Funatake, Nancy I Kerkvliet
European Journal of Immunology|December 22, 2006
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responsesCarl E Ruby, William L Redmond, Daniel Haley, et al.
Journal for Immunotherapy of Cancer|June 28, 2014
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanomaHoward L Kaufman, Carl E Ruby, Tasha Hughes, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
IL-12 is required for anti-OX40-mediated CD4 T cell survivalCarl E Ruby, Ryan Montler, Rongxui Zheng, et al.
European Journal of Immunology|March 15, 2011
OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survivalNicole A Vasilevsky, Carl E Ruby, Peter J Hurlin, et al.
Journal of Leukocyte Biology|April 10, 2014
Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell primingMichelle Farazi, Zachary Cohn, Justine Nguyen, et al.
Pageof 3